Current Issue: September 2009
Seattle has long fancied itself a world business capital, especially when it comes to computer software, coffee or internet retailing. A lot of local people certainly made a lot of money from national—even international—success in those and other businesses.
Even though the subject of ethics often makes for news stories, this wasn't supposed to be one. No, it began as an executive education piece that would examine whether companies are investing in training and continuing education these days, what with the soft economy and all.
Just after 9/11 Damian Martin was going through a professional transition. Realizing that the sputtering economy would make the search take a bit longer than he liked, he decided to stop in at a few temp agencies to see what might be available. None of them called him back.
It's not uncommon for executives to talk about their company's market opportunity and potential profitability. It is, after all, why they are in business in the first place. However, rare is the biotech company that is open to discussing such things, especially in the same breath as their more altruistic goal of managing disease. Rochester-based Martell Biosystems, Inc.